Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.
about
Evidence-based hypertension treatment in patients with diabetesModulation of glucose metabolism by the renin-angiotensin-aldosterone systemMetabolic actions of angiotensin II and insulin: a microvascular endothelial balancing actValsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trialSodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusionsDietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humansEffects of aldosterone on insulin sensitivity and secretion.Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension.The renin angiotensin aldosterone system and insulin resistance in humans.The endothelium in diabetes: its role in insulin access and diabetic complicationsAltered Skeletal Muscle Fatty Acid Handling in Subjects with Impaired Glucose Tolerance as Compared to Impaired Fasting Glucose.The renin-angiotensin-aldosterone system and glucose homeostasis.Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms.Increased cord blood angiotensin II concentration is associated with decreased insulin sensitivity in the offspring of mothers with gestational diabetes mellitus.The renin-angiotensin system in the pathophysiology of type 2 diabetes.Tissue Renin-Angiotensin systems: a unifying hypothesis of metabolic disease.The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches.Cardiometabolic crosstalk in obesity-associated arterial hypertension.Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure.Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers.Oxidative stress: link between hypertension and diabetes.Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension.Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension.Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients.The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.Medications that cause weight gain and alternatives in Canada: a narrative review
P2860
Q26851738-2AC0A488-3781-44FE-A485-F5EDB4A57A60Q27026157-3E1AFAC8-4132-48B0-AC3B-E010112DF350Q28390079-2714F500-BC86-4E19-A886-067BC4B06801Q28727779-7756574B-69D7-4C39-A734-B581AEDCA3EEQ33820904-BD18F670-C4BF-47AF-9599-DFCABC2368EFQ34284717-C89D77D7-3BE1-40EA-B8EA-C0A3713FF757Q34614820-253A66DC-211C-48E2-8DD3-3663E058C991Q35751342-03B86E11-3ADD-427C-B0D3-62AB2352B28EQ36550987-3EBFF3A9-CE4D-404C-81B3-011528A08647Q36672866-1C7DC0A4-F427-48C0-A0B9-2D9493D468F8Q36732144-F470E311-0F60-40BE-A7A6-F1E81A1FE950Q37924374-A109281A-22C9-4AFA-8022-39E577630918Q37973874-B9A6258E-2572-4D55-B075-8C026FFA4AD7Q38002327-9E11C797-564B-429B-9083-4FF1EDD70F62Q38044215-65143BE1-B31B-44C3-926C-C630522A53F5Q38193086-51CC754B-1516-444E-86E0-6E7B2FE13D8DQ38332289-569A629F-24B4-4B7F-9C16-52023E64C907Q38767511-91E5BAE4-8998-4E00-9BD3-6A38C0C71E91Q38885540-AEA5595D-789E-498C-A533-F0556CE51D9EQ39483579-A31117A8-1997-4904-A2A7-85D24B0911E0Q41790884-0A50C124-2A78-4CCD-A014-50085ED842C4Q42027723-933D8759-F725-4D15-9F81-B59AA16E06E1Q42350492-80AD5B14-47FA-4D32-AC52-E1BFD89FF857Q42830503-B12D35C3-D765-4EC5-81A5-1C49863CC1D8Q48249984-D286C01E-24A0-449B-8C8D-7189451EF96CQ51563912-867DD9BE-04FC-46E5-8A29-B2DCD4A22504Q52676366-F1FECAB2-87AE-4945-8272-9E7B2AF15120Q58729864-44709EBB-BE49-4412-9D75-D10968BB6FC5
P2860
Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Valsartan improves {beta}-cell ...... a randomized controlled trial.
@ast
Valsartan improves {beta}-cell ...... a randomized controlled trial.
@en
Valsartan improves {beta}-cell ...... a randomized controlled trial.
@nl
type
label
Valsartan improves {beta}-cell ...... a randomized controlled trial.
@ast
Valsartan improves {beta}-cell ...... a randomized controlled trial.
@en
Valsartan improves {beta}-cell ...... a randomized controlled trial.
@nl
prefLabel
Valsartan improves {beta}-cell ...... a randomized controlled trial.
@ast
Valsartan improves {beta}-cell ...... a randomized controlled trial.
@en
Valsartan improves {beta}-cell ...... a randomized controlled trial.
@nl
P2093
P2860
P356
P1433
P1476
Valsartan improves {beta}-cell ...... a randomized controlled trial.
@en
P2093
Chantalle C M Moors
Ellen E Blaak
Gijs H Goossens
Marc M H Hermans
Michaela Diamant
Nynke J van der Zijl
P2860
P304
P356
10.2337/DC10-2224
P407
P577
2011-02-17T00:00:00Z